Trusts need not wait for NICE appraisal in planning for new drugs, NHS centre saysBMJ 2010; 341 doi: http://dx.doi.org/10.1136/bmj.c4600 (Published 20 August 2010) Cite this as: BMJ 2010;341:c4600
- Caroline White
Primary care trusts and specialist commissioners in England should plan ahead for newly licensed drugs, irrespective of whether the National Institute for Health and Clinical Excellence (NICE) has evaluated their cost and clinical effectiveness, says the NHS National Prescribing Centre.
In the first of its Tough Decisions newsletters, designed to improve local decision making on the funding and commissioning of drugs, the centre lists several new drugs that it thinks patients and doctors are likely to want. These include two oral treatments for multiple sclerosis, cladribine and fingolimod, and two drugs for chronic obstructive pulmonary …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial